Dr. Emmanuelle Charpentier
Scientific advisor and Co-Founder Scientific and Managing Director, Max Planck Unit for the Science of Pathogens Honorary Professor, Institute for Biology, Humboldt University
Prior to joining Max Planck, Emmanuelle held an Alexander von Humboldt professorship at the Helmholtz Centre for Infection Research and Hannover Medical School, Germany. For many years, she led research groups at the Laboratory for Molecular Infection Medicine at Umeå University in Sweden and at the Max F. Perutz Laboratories at the University of Vienna in Austria. Her seminal research unveiled the key mechanisms of the CRISPR/Cas9 technology, laying the foundation for the use of CRISPR/Cas9 as a highly versatile and precise gene editing tool.
Emmanuelle studied biochemistry, microbiology and genetics at the University Pierre-and-Marie-Curie in Paris, France where she received her Ph.D. in microbiology for her research performed at the Pasteur Institute. She spent several years working in the U.S., where she held research associate positions at the Rockefeller University, New York University Langone Medical Center, the Skirball Institute of Biomolecular Medicine and St. Jude Children’s Research Hospital.
Emmanuelle’s work has been recognized by numerous awards including the Breakthrough Prize in Life Sciences, the Kavli Prize in Nanoscience, the Japan Prize, the Carus Medal awarded by the Leopoldina German Academy of Sciences, the Gruber Prize in Genetics, the Princess of Asturias Award for Technical and Scientific Research, the Louis Jeantet Prize for Medicine, the Ernst Jung Prize for Medicine, the Göran Gustafsson Prize awarded by the Royal Swedish Academy of Sciences, Le Prix Jean-Pierre Lecocq from the French Academy of Sciences, the L’Oréal Unesco for Women in Science Award 2016, the 2015 Otto Warburg Medal, the Umeå University EC Jubilee Award 2015 (named for her) and the 2015 Hansen Family Award. Emmanuelle was also recognized by TIME as one of The Most Influential People in 2015.
Dr. Rodger Novak
Member of the Board of Directors and co-founder
Dr. Novak is a serial entrepreneur, long-time pharmaceutical and biotechnology senior executive who co-founded CRISPR Therapeutics AG in late 2013. He led the company as CEO until December 2017. During his tenure he IPO’d the company and was responsible for the two landmark deals with Vertex and Bayer. Currently, Dr. Novak serves CRISPR Therapeutics as President and Chair of the Board. He also serves as Executive Chair on the boards of Rockend Ltd, Cambridge, UK, and Matterhorn Biosciences, Basel, Switzerland.
Before CRISPR Therapeutics Dr. Novak was Global Head Infectious Diseases, Sanofi, Paris, France. His responsibility included discovery, research and development, and late stage clinical development of anti-infectives, including diseases of the developing world. In early 2006 Dr. Novak became COO of Nabriva Therapeutics, an antibacterial development company in Vienna, Austria, he co-founded. Nabriva was a spin-out from Sandoz/Novartis, where Dr. Novak served as Vice-Head of the Antibiotic Research Institute.
Dr. Novak received his medical degree in Germany in 1993 and his medical license for the USA in 1994. From 1996 to 2001 he was a postdoctoral fellow at the Rockefeller University, the Skirball Institute, NYU Medical Center, and St Jude Children’s Research Hospital. In 2001, he was appointed as tenured Professor for Microbiology at the Vienna Biocenter, Austria. Dr. Novak authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell, provided key contributions in different scientific textbooks in the fields of anti-infectives, genetics and personalized medicine. He is also a co-inventor of several patents.
Chairman of the Board of Directors and co-founder
Shaun brings almost 20 years of experience in emerging healthcare companies as an entrepreneur, investor and advisor. Previously, Shaun served as CFO and a member of the board of directors of CRISPR Therapeutics, a company that he co-founded in 2013 that is focused on the therapeutic applications of the CRISPR/Cas9 technology. Prior to that he was a partner and one of the founding team members of Nomura Phase4 Ventures, a London-based venture capital group investing in emerging healthcare companies where he gained particular experience investing in cell and gene therapy companies. Prior to that, he worked with Nomura International’s healthcare corporate finance group advising emerging healthcare companies on M&A and capital raisings.
Shaun is a CFA® charterholder and holds an MSc in cell biology and immunology from the University of British Columbia in Canada.
We have decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development.
Eric serves as the CEO of ERS Genomics. He joined ERS from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer and was responsible for commercializing Horizon’s genome editing technologies as well as overseeing research and development. Over the course of his career he has held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences where he was responsible for commercializing gene-editing technologies and executed licensing deals with more than 25 major biotechnology and pharmaceutical companies. Eric holds a degree in microbiology and immunology from the University of California, Berkeley.
Michael Arciero, JD
Vice President IP & Commercial Development
Michael serves as Vice President of Intellectual Property and Corporate Development with over 15 years’ experience in corporate and academic transactions. Prior to ERS, Michael served as Director of Technology Commercialization and New Ventures for the USC Stevens Center for Innovation. While there, he led the technology transfer and corporate alliance teams supporting innovation across all disciplines stemming from over $900M in annual research expenditures. As licensing attorney for Diversa Corporation (now BASF), Michael was responsible for the negotiation and drafting of complex transactions in support of business and research development. Michael received his bachelor’s degree in Biology from the University of California, San Diego and his Juris Doctorate from the University of San Diego School of law.
Vice President for Business Development & Licensing for North America
Jon Kratochvil has just joined ERS Genomics as the Vice President for Business Development and Licensing for North America.
Most recently Jon was the Director of Business Development and Licensing at MilliporeSigma in St. Louis. Jon and his team were responsible for all global business development opportunities for MilliporeSigma’s gene editing and novel modalities technologies. Prior to joining MilliporeSigma, he was the COO for QMAXX Products Group Inc., a specialty chemicals company in St. Louis, Missouri that developed novel anti-corrosive lubricants for industrial and consumer uses.
Jon was the Business Development Director for Washington University for 16 years managing a portfolio of over 1000 life science technologies which generated in excess of $70 million in revenue during his tenure. He was also involved with helping establish several University start-up companies and has served as a business expert on several government and community advisory boards.
He was employed for over a decade as a licensing manager and the competitive intelligence analyst for Abbott Laboratories diagnostics division, working on novel detection platforms and pharmacogenetics. He is an inventor on over 40 patents and patent applications.
Jon received a BS in Biology from Rutgers University. He also received graduate degrees from Northwestern University in Microbiology/Immunology and Loyola University in Chicago in Law.
Sr. Director, Business Development & Licensing
Dan brings over 20 years of experience in business development and licensing, mostly at therapeutic focused biotech companies. Among these, he led the licensing efforts for clinical stage products at WEX Pharmaceuticals in Vancouver, Canada. As head of the Business Development group at Inex Pharmaceuticals in Vancouver, Canada he was responsible for licensing preclinical and clinical stage therapeutic products and drug delivery technologies. Prior to this, he negotiated research collaboration and in-license agreements at Cambridge, Massachusetts based Genetics Institute, Inc. He received his bachelor’s degree in Biochemical Sciences from Harvard.
Head of Finance
Tracy brings over 20 years finance experience within various industries including construction, telecoms and pharmaceutical healthcare. Tracy is a qualified accountant with CPA Ireland.